Trial of D-Cycloserine in Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Adult, Cognition, Cycloserine, Dopamine, Female, Glutamic Acid, Human, Male, Receptors, N-Methyl-D-Aspartate, Schizophrenia, Serotonin, Quality of Life, Cycloserine -- *therapeutic use, Dopamine -- blood, Dopamine -- cerebrospinal fluid, Glutamic Acid -- blood, Glutamic Acid -- cerebrospinal fluid, Serotonin -- blood, Serotonin -- cerebrospinal fluid
Eligibility Criteria
Inclusion Criteria: Diagnosis of Schizophrenia as per DSM IV criteria Have been treated for at least 6 months with any conventional neuroleptic Have prominent negative symptoms as defined by a total score of 40 or greater on the scale for the assessment of negative symptoms (SANS) Exclusion Criteria: Active alcohol or drug abuse Unstable Medical Illness, seizure disorder, or other serious neurological disorder Pregnant or Nursing Unable to complete a cognitive battery
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
D-Cycloserine
Placebo
Subjects were given 50 mg/day of D-Cycloserine for 24 weeks
Participants were given 50 mg/day of Placebo for 24 weeks.